Literature DB >> 33609933

Comprehensive pathogen detection for ocular infections.

Thuy Doan1, Malaya K Sahoo2, Kevin Ruder3, ChunHong Huang2, Lina Zhong3, Cindi Chen3, Armin Hinterwirth3, Charles Lin4, John A Gonzales5, Benjamin A Pinsky6, Nisha R Acharya5.   

Abstract

BACKGROUND: Molecular diagnostics such as pathogen-directed PCRs have transformed testing for ocular infections since the late 1990s. Although these assays remain important diagnostic tools for samples with low biomass, the lack of diagnostic range motivates alternative molecular approaches for ocular infections. The aim of this study was to determine the performance of a high-throughput RNA sequencing approach, RNA-seq, to detect infectious agents in ocular samples from patients with presumed ocular infections.
METHODS: We compared the performance of RNA-seq to pathogen-directed PCRs using remnant nucleic acids from 41 aqueous or vitreous samples of patients with presumed ocular infections. Pathogen-directed PCRs were performed at the CLIA-certified Stanford Clinical Virology Laboratory. RNA-seq was performed in a masked manner at the Proctor Foundation at the University of California San Francisco. Percent positive and negative agreement between the two testing approaches were calculated. Discordant results were subjected to orthogonal testing.
RESULTS: The positive percent agreement between RNA-seq and pathogen-directed PCRs was 100% (95% confidence interval (CI): 78.5%-100%). The negative percent agreement was 92.6% (95% CI: 76.6%-97.9%). RNA-seq identified pathogens not on the differential diagnosis for 9.7% (4/41) of the samples. Two pathogens solely identified with RNA-seq were confirmed with orthogonal testing.
CONCLUSIONS: RNA-seq can accurately identify common and rare pathogens in aqueous and vitreous samples of patients with presumed ocular infections. Such an unbiased approach to testing has the potential to improve diagnostics although practical clinical utility warrants additional studies.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CMV; Eye; PCR; Pithomyces; RNA-seq; Uveitis; rubella

Mesh:

Year:  2021        PMID: 33609933      PMCID: PMC7954984          DOI: 10.1016/j.jcv.2021.104759

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  16 in total

1.  Incorporating uncertainty into medical decision making: an approach to unexpected test results.

Authors:  Matt T Bianchi; Brian M Alexander; Sydney S Cash
Journal:  Med Decis Making       Date:  2008-09-23       Impact factor: 2.583

2.  Biome representational in silico karyotyping.

Authors:  Valliammai Muthappan; Aaron Y Lee; Tamara L Lamprecht; Lakshmi Akileswaran; Suzanne M Dintzis; Choli Lee; Vincent Magrini; Elaine R Mardis; Jay Shendure; Russell N Van Gelder
Journal:  Genome Res       Date:  2011-02-10       Impact factor: 9.043

3.  Moving From Syndromic Description to Etiologic Diagnosis for Uveitis.

Authors:  Thellea K Leveque; Debra A Goldstein
Journal:  JAMA Ophthalmol       Date:  2019-04-01       Impact factor: 7.389

4.  STAR: ultrafast universal RNA-seq aligner.

Authors:  Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras
Journal:  Bioinformatics       Date:  2012-10-25       Impact factor: 6.937

5.  Metagenomic DNA Sequencing for the Diagnosis of Intraocular Infections.

Authors:  Thuy Doan; Nisha R Acharya; Benjamin A Pinsky; Malaya K Sahoo; Eric D Chow; Niaz Banaei; Indre Budvytiene; Vicky Cevallos; Lina Zhong; Zhaoxia Zhou; Thomas M Lietman; Joseph L DeRisi
Journal:  Ophthalmology       Date:  2017-05-16       Impact factor: 12.079

6.  Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distribution.

Authors:  T Doan; A Hinterwirth; L Worden; A M Arzika; R Maliki; A Abdou; S Kane; L Zhong; S L Cummings; S Sakar; C Chen; C Cook; E Lebas; E D Chow; I Nachamkin; T C Porco; J D Keenan; T M Lietman
Journal:  Nat Med       Date:  2019-08-12       Impact factor: 53.440

7.  Clinical metagenomics for infectious corneal ulcers: Rags to riches?

Authors:  Lawson Ung; Paulo J M Bispo; Thuy Doan; Russell N Van Gelder; Michael S Gilmore; Thomas Lietman; Todd P Margolis; Michael E Zegans; Cecilia S Lee; James Chodosh
Journal:  Ocul Surf       Date:  2019-10-25       Impact factor: 6.268

8.  Dual-target, real-time PCR for the diagnosis of intraocular Toxoplasma gondii infections.

Authors:  Carlos A Gomez; Malaya K Sahoo; Ghazala Yasmeen Kahn; Lina Zhong; José G Montoya; Benjamin A Pinsky; Thuy Doan
Journal:  Br J Ophthalmol       Date:  2019-01-12       Impact factor: 4.638

9.  Illuminating uveitis: metagenomic deep sequencing identifies common and rare pathogens.

Authors:  Thuy Doan; Michael R Wilson; Emily D Crawford; Eric D Chow; Lillian M Khan; Kristeene A Knopp; Brian D O'Donovan; Dongxiang Xia; Jill K Hacker; Jay M Stewart; John A Gonzales; Nisha R Acharya; Joseph L DeRisi
Journal:  Genome Med       Date:  2016-08-25       Impact factor: 11.117

View more
  3 in total

1.  Interepidemic Respiratory Syncytial Virus during the COVID-19 Pandemic.

Authors:  ChunHong Huang; Malaya K Sahoo; Michelle Verghese; Mamdouh Sibai; Daniel Solis; Kenji O Mfuh; Jason Kurzer; Catherine A Hogan; Thuy A Doan; Benjamin A Pinsky
Journal:  Microbiol Spectr       Date:  2022-04-25

2.  Vaccine-Associated Measles Encephalitis in Immunocompromised Child, California, USA.

Authors:  Cristina Costales; Malaya K Sahoo; ChunHong Huang; Carolina V Guimaraes; Donald Born; Lauren Kushner; Hayley A Gans; Thuy A Doan; Benjamin A Pinsky
Journal:  Emerg Infect Dis       Date:  2022-04       Impact factor: 6.883

3.  Outpatient human coronavirus associated conjunctivitis in India.

Authors:  N Venkatesh Prajna; Prajna Lalitha; Gonugunta Vishnu Teja; Rameshkumar Gunasekaran; Sankalp S Sharma; Armin Hinterwirth; Kevin Ruder; Lina Zhong; Cindi Chen; Michael Deiner; ChunHong Huang; Benjamin A Pinsky; Thomas M Lietman; Gerami D Seitzman; Thuy Doan
Journal:  J Clin Virol       Date:  2022-09-27       Impact factor: 14.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.